rgx-202
Gene therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 5, 2018 (NCT03597581)
Timeline
Indications
Mechanism of action
- Dystrophin pre-mRNASupplementation
Dystrophin pre-mRNA supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05983367 | Phase 2 | Oct 10, 2023 | Inspirna, Inc., Union Therapeutics |
| NCT05693142 | Phase 1/Phase 2 (Phase 2) | Jan 4, 2023 | Regenxbio Inc. |
| NCT03597581 | Phase 1 | Jun 5, 2018 | Inspirna, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Inspirna, Inc. | For profit | 2 | 2 | 2 | 2018 |
| Regenxbio Inc. | For profit | 1 | 1 | 1 | 2023 |
| Union Therapeutics | For profit | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1